BerGenBio ASA (LON:0RU5)

Market Cap	4.97M
Revenue (ttm)	59.62K
Net Income (ttm)	-9.79M
Shares Out	n/a
EPS (ttm)	-0.28
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,372
Average Volume	14,930
Open	1.778
Previous Close	1.800
Day's Range	1.778 - 1.778
52-Week Range	0.077 - 5.300
Beta	n/a
RSI	31.12
Earnings Date	Apr 29, 2025

About BerGenBio ASA

BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat drug resistant, metastatic cancers, and respiratory diseases in Norway. The company’s lead clinical asset is the Bemcentinib (BGB016), an inhibitor of AXL receptor tyrosine kinase (AXL), which is in phase 1b/2a clinical trial to treat non-small cell lung cancer; and (BGBC008), which is in phase 2 clinical trial to treat second-line non-small cell lung cancer (2L NSCLC). It develops Bemcentinib, which is in preclinical trial to treat acute...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2007
• Employees: 15
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0RU5

Financial Performance

In 2024, BerGenBio ASA's revenue was 848,000, an increase of 139.55% compared to the previous year's 354,000. Losses were -139.28 million, -26.85% less than in 2023.

Financial numbers in NOK